CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia

NCT07652905 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Plasma Cell Leukemia (PCL)

Interventions

DRUG: CM336
DRUG: Isatuximab
DRUG: Bortezomib
DRUG: Lenalidomide

Sponsor

Institute of Hematology & Blood Diseases Hospital, China